Compare Enveric Biosciences Inc (ENVB) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Hilton Hotels Corporation Common Stock trades at $323.19 (market cap $72.14B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 10783.3× Enveric Biosciences Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Hilton Hotels Corporation Common Stock for 138 Days on average.
| ENVB | HLT | |
|---|---|---|
Market Cap | $6.69M | $72.14B |
Volume | 41,141 | 862,817 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $350.22 |
52-Week Low | $1.27 | $256.96 |
Typical Hold Time | 14 Days | 138 Days |
Enterprise Value | -$1.60M | $85.15B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Hilton Worldwide (HLT) trades at $323.29, up 0.21% on the day, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported revenue of $12.04B in 2025, with net income of $1.46B and consistent quarterly EPS beats. Recent news highlights upcoming Q3 2026 earnings and positive travel trends for 2027.
Outlook remains positive with a consensus price target of $348.11, though high debt levels and valuation multiples pose risks. Earnings growth and global expansion in Asia present opportunities, but investors should monitor interest expense and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
